New drug sabirnetug aims to slow Alzheimer's decline
Disease control
Ongoing
This Phase 2 trial tests whether sabirnetug, given as an IV infusion every four weeks, can slow cognitive and functional decline in people with early Alzheimer's disease. About 542 participants will receive either sabirnetug or a placebo. The main outcome is change in a combined …
Phase: PHASE2 • Sponsor: Acumen Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC